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inherited connective tissue disorder clinically diagnosed by the
presence of significant joint hypermobility and associated skin
manifestations. This article presents a large-scale study that
reports the lived experience of EDS-HTpatients, the broad range
of symptoms that individuals with EDS-HT experience, and the
impact these symptoms have on daily functioning. A 237-item
online survey, including validated questions regarding pain and
depression, was developed. Four hundred sixty-six (466) adults
(90% female, 52% college or higher degree) with a self-reported
diagnosis of EDS-HTmade in a clinic or hospital were included.
The most frequently reported symptoms were joint pain (99%),
hypermobility (99%), and limb pain (91%). They also reported a
high frequency of other conditions including chronic fatigue
(82%), anxiety (73%), depression (69%), and fibromyalgia
(42%). Forty-six percent of respondents reported constant
pain often described as aching and tiring/exhausting. Despite
multiple interventions and therapies, many individuals (53%)
indicated that their diagnosis negatively affected their ability to
work or attend school. Our results show that individuals with
EDS-HTcanexperience awidearrayof symptomsandco-morbid
conditions. The degree of constant pain and disability experi-
enced by the majority of EDS-HT respondents is striking and
illustrates the impact this disorder has on quality of life aswell as
the clinical challenges inherent in managing this complex con-
nective tissue disorder.  2013 Wiley Periodicals, Inc.
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DOI 10.1002/ajmg.a.36293Ehlers–Danlos syndrome (EDS) is a group of highly variable
heritable connective tissue disorders characterized by a wide range
of clinical manifestations that most often include skin manifesta-2013 Wiley Periodicals, Inc.tions and joint hypermobility. Some forms of EDS (i.e., classic,
vascular) are caused by defects in the synthesis, processing, secre-
tion, or stability of fibrillar collagen molecules; which is a major
structural component of connective tissue, skin, vasculature, ten-
dons, and joint ligaments. The variety of symptoms, in the different
forms of EDS, overlap in the clinical presentation. Classic type EDS,
associated with mutations in COL5A1 and COL5A2, involves
mainly skin hyperextensibility, abnormal wound healing, and
some hyperextensibility. Vascular type EDS, considered the most
life threatening, involves severe fragility of connective tissues with
arterial and gastrointestinal ruptures, and complications of surgical
interventions. Vascular type EDS is mostly commonly associated
with mutations in COL3A1 [Germain and Herrera-Guzman, 2004;
Fernandes and Schwartz, 2008]. However, one of the most preva-
lent, but often under-diagnosed, forms of EDS is hypermobility2981
2982 AMERICAN JOURNAL OF MEDICAL GENETICS PART Atype EDS (EDS-HT) for which the molecular basis remains largely
unknown [Tinkle, 2008; Tinkle et al., 2009].
EDS-HT is associated with chronic, frequently debilitating,
musculoskeletal pain, and ongoing joint hypermobility, often
resulting in severe arthritis and physical limitations [Castori
et al., 2012]. There are also anecdotal reports of a high incidence
of co-morbid conditions including fatigue, fibromyalgia,
migraines, and irritable bowel syndrome [Sacheti et al., 1997;
Adib et al., 2005; Tinkle, 2008; Tinkle et al., 2009; Castori
et al., 2010; Rombaut et al., 2010]. The current diagnostic criteria
to establish a clinical diagnosis of EDS-HT in adults includes a
hypermobility score of 5 or greater on the 9-point Beighton scale,
soft skin with normal or minimally increased extensibility and
absence of fragility or other significant skin or soft tissue abnor-
malities. The diagnosis may also be supported by the occurrence
of minor criteria that include joint dislocations, easy bruising,
functional bowel disorders, chronic limb/joint pain, or a positive
family history [Beighton et al., 1998]. More recent work has
highlighted the increase in additional health complaints including
musculoskeletal, pseudoneurological, and gastrointestinal symp-
toms [Maeland et al., 2011].
Though there are diagnostic criteria, EDS-HT continues to
be underdiagnosed. The condition is difficult to recognize as
individuals may present with chronic pain without other major
symptoms other than increased joint hypermobility and no other
objective findings on imaging or laboratory studies. Studies
have found that only 10% of physicians referring EDS-HT patients
to rheumatology clinics realized that their joint hypermobility
was the underlying cause of their patients’ pain [Adib et al.,
2005]. It has been proposed that EDS-HT may be the occult
underlying diagnosis for many chronic somatic pain syndromes
[Castori et al., 2013].
This chronic pain can lead to considerable psychological distress
and reduced quality of life. Current treatmentsmodalities for EDS-
HT are of limited benefit and are restricted to symptomatic
management, often with pain medications and physical therapy
[Sacheti et al., 1997; Rombaut et al., 2011; Castori et al., 2012].
Treatment is generally ineffective or suboptimal and individuals
with a diagnosis of EDS-HT often experience depression and a
lower quality of life that limit their lifestyles, aswell as affecting their
psychological well being [Ainsworth and Aulicino, 1993;
Tinkle, 2008]. Baeza-Velasco et al. [2011] found that chronic
pain in these individuals with a diagnosis of EDS-HT is often
associated with depression and anxiety that is amplified by a lack of
recognition and knowledge of the syndrome by managing clini-
cians. There is also a body of literature that suggests that EDS-HT
disease-related symptoms severely affected individuals’ quality of
life. Other problematic issues emphasized in this population in-
clude stigmatization, altered life plans, and constant fear of the pain
and its progression [Berglund et al., 2000]. New recommendations
publishedbyCastori et al. [2012] suggest extensive lifestyle counsel-
ing including a multidisciplinary team.
To date, there have been limited studies that have focused on
comprehensively describing the experience of living with EDS-HT.
Castori et al. [2010] surveyed 21 EDS-HTpatients seen in a genetics
clinic, Castori et al. described the musculoskeletal, gastrointestinal,
neurological, cardiovascular, urogynecological, and ear-nose-throat symptoms they experienced but failed to explore their
psychological state. While other studies by Voermans et al.
[2009, 2010] have focused on specific types of symptoms associated
withEDS-HT, such as fatigue andpain, theydidnotdescribe the full
range of clinical symptoms experienced by their study population.
In a sample of 273 individuals with EDS (162 of which with EDS-
HT) they looked specifically at the impact of pain and concluded
that pain is common in severe EDS. Recently, Remvig et al. [2011]
described the need for a broader appreciation of the full scale of
multi-system involvement in EDS-HT. Maeland et al. [2011] have
also reported that up to 98% of individuals with EDS-HT report
substantial complaints in the last 30 days.
The complex health issues that surround a diagnosis of EDS-HT
demand a comprehensive evaluation/catalogue of both the clinical
and lived experience tobetter aid the practitioner inmanaging these
patients. Our study objective was to comprehensively describe the
experience of living with a diagnosis of EDS-HT from the patient
perspective. We surveyed a large number of individuals with a
diagnosis of EDS-HT to describe symptoms and pain experienced
by individuals with this condition.METHODS
Recruitment
This study was conducted from September 2009 to April 2010.
Patients with a clinical diagnosis of EDS-HT were recruited from
two sources. The first recruitment arm was through two support
groups: the Ehlers–Danlos National Foundation (EDNF) and the
local Ehlers–Danlos Support Group (AnnArborEDS@gmail.com).
Following approval of the study by their boards of directors, the
study was announced on each group’s website with a direct link to
a web-based survey (content described below). The study an-
nouncement specified the inclusion criteria that individuals
must be over 18 years of age and by their self-report to have a
clinical diagnosis of EDS-HT made by a physician. The second
recruitment arm was through the University of Michigan Medical
Genetics Clinic. Adult patients seen in the past 5 years with a
confirmed clinical diagnosis EDS-HT were sent a letter of recruit-
ment and provided with the address to the web-based survey. The
survey was accessible for a 2-month period. This study was ap-
proved by the University of Michigan Internal Review Board
(HUM00031584).
Study Instrument
A 237-item survey instrument was developed by the research team
that ascertained the respondents’ self-reported information about
(1) demographics, (2) mechanism for EDS-HT diagnosis, (3)
symptom/comorbid conditions, (4) pain and depression, (5) im-
pact on of diagnosis on work and education, and (6) sources of
support (Table I). The survey instrument contained both validated
measures (71 items) and those that were developed specifically for
this study. As the goal of this study was to explore the perceived
impact of an EDS-HT diagnosis on an individual’s life, we gathered
this information by participant self-report. The survey questions
that elicited participant reports of symptoms/comorbid conditions
and treatments were developed from an analysis of the current
TABLE I. Survey Instrument Components
Instrument Authors Description Focus as applied to this research
Symptom catalog Research Team Systematic checklist of current
symptoms related to disease,
duration, frequency, age of onset, and
priority in terms of a ranking of the
symptoms that have the most effect
Create a comprehensive description of
symptoms experienced by individuals
with EDS-HT.
Treatment catalog Research Team Self-report checklist of current and past
caregivers, treatments tried, duration,
whether tried in the past or currently,
relative efficacy
Explore the management options utilized
by individuals with EDS-HT.
McGill Pain Questionnaire
(short form)
Melzack [1987] Scale that measures intensity and
quality of pain by requesting
participants to rate pain through 15
verbal descriptors on a 0–3 rating
scale. Widely used for assessment of
clinical pain.
Describes the level of pain experienced
by EDS-HT patients.
The Center for Epidemiologic
Studies Depression
Scale (CES-D)
Radloff [1977] Scale that asks how individuals have felt
in the last week; a score of greater
than 16 on this test indicates
“probable depression.”
Assess the psychological impact of EDS-
HT. This scale was only completed
when individuals responded “Yes” to
having ever experienced depression.
TABLE II. Demographics of the Study Population (n¼ 466)
%
Sex
Female 89.9
Male 10.1
Race
White/Caucasian 95.3
Hispanic 2.1
Asian 1.5
Black/African American 0.9
Other 6.2
Education
Some high school 1.9
Completed high school 8.8
Some college 36.7
Bachelor’s degree 20.2
Graduate level 25.8
Doctorate 6.2
Geographic location
MURRAY ET AL. 2983literature by the research composed of physicians and genetic
counselors who regularly work with a individuals with a diagnosis
of EDS-HT. An integral component of the survey development
included consultationwith the leader of a local EDS support group.
The survey instrument was converted into an online form and
administered through Qualtrics survey software.
Statistical Analysis
Data were analyzed using PASW (Predictive Analytic Software)
Statistics 17. Responses were excluded if the respondent did not
reach the end of the survey, and/or if they reported their diagnosis
was made anywhere other than in a clinic/hospital. Analysis was
performed using descriptive statistics: frequencies and means, as
well as Pearson chi-square tests and correlations. Reported fre-
quencies andmeans were determined to be significant using a one-
sided t-test. Values were considered significant when analysis by
t-test determined that the value in this population was significantly
different than expected by chance alone.Midwest 25.5
Northeast 17.8
Southeast 12.7
Southwest 8.8
Northwest 7.5
Central Southern 5.4
Country outside the USA 21.7RESULTS
Demographics of the Study Population
Out of the initial 617 respondents (580 from the support group
websites, and37 identified fromtheUniversity ofMichiganMedical
Genetics Clinic), the final data analysis group consisted of 466
individuals. Respondents were excluded if they did not reach the
endof the survey (44), or if theydidnot report that their diagnosis of
EDS-HT had been made in a clinic or hospital (107). As this was a
web-based survey, the response rate is unknown, however of those
identified from the Medical Genetics Clinic, there was a 41%
response rate from this group (37/91), but this was only 6% of
the overall response. Demographics of the study population are
listed in Table II. The population was 95%Caucasian and 89% had
completed some college or higher; notably, 22% had Master’s orDoctorate degrees. Sixty-nine percent of respondents resided with-
in 30miles of a major academic healthcare facility.Clinical Symptoms and Related Diagnoses
The majority of participants reported being diagnosed in either a
genetics or rheumatology clinic (Table III). Fifty-six percent of
participants had been seen in a genetics clinic at some point in the
TABLE III. Clinical Diagnosis: Setting Where Diagnosis Established
and Reported Primary Caregiver
Clinic setting
Diagnosis
established (%)
Primary
caregiver (%)
Primary care 5.8 41.5
Genetics 28.6 6.2
Rheumatology 1.5 18.9
Orthopedics 7.3 6.9
Physical medicine 1.5 4.9
Pediatrics 1.3 0.9
Pain clinic 0.4 6.0
Other 3.9 9.0
2984 AMERICAN JOURNAL OF MEDICAL GENETICS PART Apast. Forty-two percent of participants reported that the main
physician who manages their diagnosis was their primary care
physician and 19 percent reported that a rheumatologist provides
primary clinical management of their disease.
The significance of a diagnosis of EDS-HT on the health of
respondents was catalogued by assessing the type of symptoms,
frequency, age of onset, and reported impact on participants’ lives.
Respondents reported experiencing a broad range of symptoms and
diagnoses that impacted the following categories: their joints
(99%), cardiovascular system (96%), gastrointestinal system
(96%), skin (95%), neurological/psychological manifestations
(88%), and genitourinary system (67%) (Fig. 1). Joint symptoms
were themost common category reported, which is consistent with
the EDS-HT clinical diagnostic criteria. Among 39 possible symp-
toms or diagnoses surveyed in the study, the most commonly
reported symptoms were joint pain, hypermobility, limb pain,
and joint subluxations. Participants also frequently reported dizzi-
ness and chronic fatigue. In Figure 1, starred symptoms represent
those that were reported by a significant number of respondents
rather than expected by chance (P<< 0.001).
Thirty-three percent of participants reported experiencing be-
tween 15 and 25 symptoms and/or clinical diagnoses. Themajority
of respondents’ reported that their symptoms presented before the
age of 30. Hypermobility and skin findings were noted to present in
childhood (under age 18) for amajority of individuals. A significant
proportion of participants reported that joint pain, dislocations,
and subluxations began under the age of 18 (79% of respondents).
For respondentswithdepression, anxiety, andchronic fatigue ageof
onset range between 18 and 30 years of age.
A significant number of respondents reported experiencing
depression (69%) and anxiety (73%). Respondents who indicated
that they had experienced depression were then prompted to
complete the Center for Epidemiologic Studies Depression Scale
(CES-D). Of those that filled out the CES-D (321/466), 98% had
elevated scores; a score of over 16 is reported as an increased
susceptibility for depression (range of scores 1–46) [Radloff,
1977]. Figure 2 shows the impact that participants reported these
symptoms have on their lives.Pain and Depression
Respondents reported chronic pain and a large proportion (67%)
reported that the pain as constant, as opposed to intermittent(experienced several times a day) (22%), multiple times per week
(6.5%), once per week (1.6%), or once per month (1.6%). Only
0.6% of the study respondents reported they did not experience
pain on a regular basis. Those individuals who reported a higher
levels of pain were also more likely to report experiencing a
significantly higher number of symptoms (P< 0.05). The most
commonly reported pain types reported were tiring/exhausting
pain (93%) and aching (80%) (Fig. 3). Participants with tiring and
exhausting pain also reported symptoms of chronic fatigue (92%),
depression (78%), and fibromyalgia (56%). For respondents with
tiring and exhausting pain, 42% reported taking an anti-depressant
medication.Effect of EDS-HT on Work and School
Individuals were asked to describe the effect that their diagnosis had
on their employment or education. Two hundred fifty-one respon-
dents (55%)were currently employed, 24%were only working part
time due to having EDS-HT. Of all of those working, 52% had to
change roles/take on less responsibility because of their diagnosis.
Sixty-six percent reported that their employer knew of their diag-
nosis. Fifty-four percent of the respondents who were not working
(54/466) indicated that limitations due to their diagnosis of EDS-
HTwas the reason. Therewere 119 respondents whowere currently
students, and of those, and 21 of 119 (18%) indicated that theywere
not able to enroll in a fulltime educational program as a conse-
quence of their diagnosis. There were an additional 38 respondents
who indicated they were not enrolled in school due to having
a diagnosis of EDS-HT. Of the responses regarding performances,
49/60 (82%) strongly agreed or agreed that having this diagnosis
had affected their performance at work or school and 33 (55%)
indicated that special accommodations were needed.Sources of Support
A variety of questions were asked inquiring about the support
resources utilized by this population. Fifty-seven percent reported
that they regularly read EDS literature, websites, or publications
and 11% reported currently attending support group meetings.
Participants were asked about sources of support: 62% felt sup-
ported by their family, 52% by friends, 25% by religious institu-
tions, and 24% by their employer.DISCUSSION
In this large-scale study of the lived experience of EDS-HT, par-
ticipants report a number of symptoms and comorbid diagnosis
outside of joint hypermobility alone. Important findings in these
results are the shear number of symptoms these patients experience
and the pain that accompanies them. This pain and depression that
has a destructive effect on quality of life in these individuals, which
participants report has ripple effects on their work and/or school
success. While a patient-report based survey has limitations, the
authors felt understanding the lived experience of the individual
would be critical in advising bettermanagement in this population.
These results were consistent with previous studies in that
a multidisciplinary team approach may be most effective in
FIG. 1. EDS-HT symptoms and frequency in study population. Participants were asked if they had ever experienced any of the listed 39
symptoms, frequencies of which are displayed in the figure (%). Those starred were experienced by a significant proportion of the respondent
population as described (P<< 0.001). Symptoms are grouped by type: cardiovascular, gastrointestinal, genitourinary, joints, nervous system,
psychological, or skin findings.
MURRAY ET AL. 2985managing these patients [Hakim and Grahame, 2003; Grahame,
2009; Castori et al., 2012].
Participants reported a broad range of symptoms from skin
scarring and hyperextensibility to heart palpitations, gastrointes-tinal distress, and significant psychological concerns in addition
to the expected hypermobility symptoms. A large percentage
of participants reported between 15 and 25 symptoms and/or
related clinical diagnoses, supporting the multisystemic nature
FIG. 2. Impact of EDS-HT symptoms. The mean impact that respondents reported each symptom had on their quality of life is shown.
Participants were asked to rank each symptom on a 1–5 Likert scale, (1¼ “Strongly Disagreed” that the symptom had a significant impact,
and 5¼ “Strongly Agreed” that the symptom impacted their quality of life).
2986 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aof this condition. To the patients, this diagnosis is far from
benign, and mislabeling EDS-HT as benign hypermobility is not
only misleading to patients, and providers, but it significantly
diminishes validation of the lived experience that affected
individuals report. Lack of validation may contribute to problems
with patient-health care provider interactions and, importantly,
result in suboptimal clinical management [Baeza-Velasco
et al., 2011].It has been well documented that one of the most pressing
frustrations of individuals with chronic pain is the fact that there
is a lack of objective findings to support their subjective feelings
[Berglund et al., 2010;Dowet al., 2012]. Beyond thephysical impact
of the disease, our data further indicate that a diagnosis of EDS-HT
impacts quality of life and can significantly impact psychological
well-being and the ability to function within the normal adult
environments such as work, school, and family. Our results are
FIG. 3. Type of pain experienced by EDS-HT study population. The graph shows the mean pain score reported by participants on the McGill
pain questionnaire [Melzack, 1987]. Participants ranked the pain they felt as 1 ¼“No pain,” 2 ¼“Mild pain,” 3 ¼“Moderate pain,” and 4
¼“Worst possible pain, or severe.” The mean pain score for each type of pain was calculated for all participants and is shown in the figure.
MURRAY ET AL. 2987consistent with those in smaller studies of EDS-HT patients which
have found that their health related quality of life is significantly
lower on all sections of a health related quality of life scale than
healthy gender- and age-matched controls [Rombaut et al., 2010].
This lowered quality of life can also be compounded by the fact
that a diagnosis of EDS-HTmay exist as an “invisible disability.” As
described by Davis [2005], invisible disabilities occur as “individu-
als with conditions, illnesses, and structural or biomechanical
anomalies that are life limiting but not readily discernible to
others.” Davis highlights that understanding the lived experience
of the individual is crucial to both understanding the disability and
also in diagnosing and characterizing the disorder. Our results
provide key information that will increase the visibility of the life
limiting aspects of an EDS-HT diagnosis. They highlight large gaps
in the current clinical picture of EDS-HT.
The results of this study are limited by our recruitment methods
and self-reported nature of the clinical diagnoses. As a survey-based
study it is not possible to validate symptoms or clinical diagnoses
reported by the respondents, however, this method enables us to
develop a comprehensive description of the experiences of those
whoare livingwith adiagnosis of EDS-HT that canbeused tohealth
care providers’ perspective. Diagnoses were by self-report and no
medical recordswere reviewed for confirmation.Most participants,
as noted above, reported symptoms in line with the diagnostic
criteria. The recruitment methods may have created a bias as
individuals who use EDS-HT support group websites (94% of
our respondents) may have more symptoms and a higher level
of pain than those who do not access support group resources. In
addition, those contacted directly from the clinic may have alsoused the support group resources, and as they have been seen in a
tertiary genetics center, may have different results. Response
from the clinic population, however, was not large enough to
compare these two groups. There were significantly more female
respondents (89%) than males; however, this is consistent with the
reported population of individuals who carry a diagnosis of EDS-
HT [Voermans et al., 2009].While parts of the survey use validated
survey instruments were used, other survey questions were devel-
oped by the research team and were not validated. Questions were
subject to participants’ interpretation of the study questions. No
definitions of termswere provided. The length and internet-basis of
the instrument may also have created biases.
This is a large-scale study that provides a comprehensive sum-
mary of the self-reported symptoms, clinical diagnoses, and life
experiences of individuals who have a diagnosis of EDS-HT. We
explored the lived experience of individuals with a diagnosis of
EDS-HT: their medical symptoms, perspectives on their disease,
experiences with pain and resulting disability, and support systems
to gain a deeper understanding of the morbidity that individuals’
experience. As alluded to in previous smaller studies, the data
suggest that there is more complexity to the clinical manifestations
of EDS-HT than joint hypermobility and mild skin manifestations
[Castori et al., 2010; 2012]. Documentation of the broad array of
symptoms/clinical diagnoses and effects on quality of life reported
by this population in this study has important implications for
health care providers caring for this population. Data from this and
other studies strongly support the need for better recognition,
understanding, and management of EDS-HT as a multisystemic,
often disabling condition [Hakim and Grahame, 2003; Grahame,
2988 AMERICAN JOURNAL OF MEDICAL GENETICS PART A2009; Castori et al., 2012]. In addition, due to the multiple systems
reported as affected by these individuals, this work strongly sup-
ports recent studies that a multidisciplinary approach to manage-
ment is necessary [Castori et al., 2012].
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